Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Miller

Showing results (101-110 of 313) with videos related to

Pageof 32
Sort By:
Therapeutics and Clinical Risk Management|December 31, 2020
Early Continence and Extravasation After Open Retropubic Radical Prostatectomy - Interrupted vs Continuous Suturing for Vesicourethral AnastomosisNora Köhler, Nasrin El-Bandar, Andreas Maxeiner, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|November 21, 2009
Internal validation of an artificial neural network for prostate biopsy outcomeCarsten Stephan, Henning Cammann, Martin Bender, et al.
Cancer Letters|May 28, 2008
Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinomaAzizbek Ramankulov, Michael Lein, Manfred Johannsen, et al.
BMC Cancer|July 23, 2009
Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?Angelika Tölle, Monika Jung, Michael Lein, et al.
BJU International|September 6, 2007
Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatmentHeinrich Schulte-Baukloh, Tomas H Zurawski, Helmut H Knispel, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|July 26, 2011
Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective studyAlessandra Siegmann, Dirk Bottke, Julia Faehndrich, et al.
International Journal of Cancer|May 19, 2005
Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancerSteffen Weikert, Hans Krause, Ingmar Wolff, et al.
European Urology|August 30, 2005
Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfactionHeinrich Schulte-Baukloh, Catarina Weiss, Thomas Stolze, et al.
Anticancer Research|June 9, 2016
Management of Metastatic Bone Disease Algorithms for Diagnostics and TreatmentChristian F Jehn, Ingo J Diel, Friedrich Overkamp, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 3, 2008
Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failureHeinrich Schulte-Baukloh, Hans Bigalke, Kurt Miller, et al.
Pageof 32

Showing results (101-110 of 313) with videos related to

Sort By:
Pageof 32
Therapeutics and Clinical Risk Management|December 31, 2020
Early Continence and Extravasation After Open Retropubic Radical Prostatectomy - Interrupted vs Continuous Suturing for Vesicourethral AnastomosisNora Köhler, Nasrin El-Bandar, Andreas Maxeiner, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|November 21, 2009
Internal validation of an artificial neural network for prostate biopsy outcomeCarsten Stephan, Henning Cammann, Martin Bender, et al.
Cancer Letters|May 28, 2008
Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinomaAzizbek Ramankulov, Michael Lein, Manfred Johannsen, et al.
BMC Cancer|July 23, 2009
Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?Angelika Tölle, Monika Jung, Michael Lein, et al.
BJU International|September 6, 2007
Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatmentHeinrich Schulte-Baukloh, Tomas H Zurawski, Helmut H Knispel, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|July 26, 2011
Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective studyAlessandra Siegmann, Dirk Bottke, Julia Faehndrich, et al.
International Journal of Cancer|May 19, 2005
Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancerSteffen Weikert, Hans Krause, Ingmar Wolff, et al.
European Urology|August 30, 2005
Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfactionHeinrich Schulte-Baukloh, Catarina Weiss, Thomas Stolze, et al.
Anticancer Research|June 9, 2016
Management of Metastatic Bone Disease Algorithms for Diagnostics and TreatmentChristian F Jehn, Ingo J Diel, Friedrich Overkamp, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 3, 2008
Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failureHeinrich Schulte-Baukloh, Hans Bigalke, Kurt Miller, et al.
Pageof 32